StreetAlpha.app
Home › Stocks › DYN

Dyne Therapeutics, Inc. (DYN)

Healthcare
$16.02
▼ −4.07%
LAST CLOSE · NOV 17

Dyne Therapeutics develops drug candidates for genetic neuromuscular diseases using its FORCE delivery platform. It last closed at $16.02 on Nov 17, down 4.07% on the day. The average 12-month price target from 7 analysts is $28.00 (+74.8% from the last close), with a high of $47.00 and a low of $10.00. Analyst consensus is Buy, based on the latest ratings from 7 firms (6 buy, 0 hold, 1 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in DYN, 100% of them bullish and 0% bearish. In the past 30 days there were 4 dark pool prints totaling $3.3M, the largest $928K.

AI Auto Pilots
Is DYN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$604.9M
EPS (diluted)
−$3.62
Free cash flow
−$568.8M
Valuation
Market cap
$3.0B
187.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$913.2M
At Sep 30
Debt
$200.0M
At Sep 30
Shareholder equity
$930.9M
Shares outstanding
187.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$149.3M−$149.3MFY2021FY2022: −$168.1M−$168.1MFY2022FY2023: −$235.9M−$235.9MFY2023FY2024: −$317.4M−$317.4MFY2024FY2025: −$446.2M−$446.2MFY2025

From DYN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
7firms
6 Buy0 Hold1 Sell
Each firm's latest rating on DYN in the past 90 days
Average 12-month target
$28.00
▲ 74.8% upside

Based on 7 analysts who set a price target on DYN in the past 90 days. The average target is $28.00, with a high of $47.00 and a low of $10.00, compared with the last close of $16.02.

Low $10.00Avg $28.00High $47.00
Blue marker: last close $16.02
Highest target$47.00
Average target$28.00
Lowest target$10.00
Latest rating changes
OppenheimerDowngrade
Oct 28Buy$15
HC Wainwright & Co.Maintained
Sep 30Buy$32
Piper SandlerReiterated
Sep 29Buy$47
Morgan StanleyTarget lowered
Sep 9Buy$45 → $36
JP MorganDowngrade
Sep 9Sell$10
DateFirmActionRatingPrice target
Oct 28OppenheimerDowngradeBuy$15
Sep 30HC Wainwright & Co.MaintainedBuy$32
Sep 29Piper SandlerReiteratedBuy$47
Sep 9Morgan StanleyTarget loweredBuy$45 → $36
Sep 9JP MorganDowngradeSell$10
Loading…

Technical Analysis

DYN · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 4% below its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot S1 at $15.68, and the nearest resistance the Pivot at $16.26.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 5.8%/day
Key levels
$27.3152 week high+70.5%
$20.74100 day average+29.5%
$19.30200 day average+20.5%
$17.0820 day average+6.6%
$16.73Swing high (Oct 21)+4.4%
$16.7250 day average+4.4%
$16.61Pivot R1+3.7%
$16.26Pivot+1.5%
$16.02Last close
$15.68Pivot S1−2.1%
$14.93Swing low (Oct 6)−6.8%
$14.0052 week low−12.6%
Indicators
RSI (14)41.93Middle of its rangeNeutral
MACD0.01Below its signal lineBearish
Stochastic22.5Middle of its rangeNeutral
ADX (14)20.2Weak trend
Williams %R-96.8Oversold below −80, overbought above −20Oversold
CCI (20)-75.7Oversold below −100, overbought above 100Neutral
Rate of change−11.3%Change over 10 sessionsBearish
ATR (14)$0.93Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DYN

What happened before

See how DYN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DYN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DYN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
2
100%
Bearish
0
0%
Date span
Aug 25 – Sep 8
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$3.3M
Largest print
$928K
Loading…

DYN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲185 buying vs 95 selling
  • ▲Held by funds +12.2 pts
  • ▲Funds holding +22
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding269247+8.9%
In funds' top 1054+25.0%
Held by funds114.0%101.8%+12.2 pts
New / increased59 / 12645 / 89+38.1%
Reduced / sold out60 / 3575 / 29−8.7%
Put/call ratio0.22––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DYN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DYN is in one of them and how their past DYN trades turned out.

DYN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DYN in an article yet. Here's the latest on the wider market.

About Dyne Therapeutics

Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops drug candidates for muscle diseases caused by genetic changes. Its FORCE platform attaches a payload, such as an oligonucleotide or enzyme, to an antibody fragment that binds to a receptor found on muscle cells, aiming to carry treatments to muscle tissue and the central nervous system. The company's candidates target conditions including Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy and Pompe disease. Its candidates are still in clinical trials and not yet sold, with patients as the intended end users.

Headquarters
Waltham, MA